Company intelligence / Profile preview
Enveric Biosciences
- Ownership
- Public · ENVB
- Development stage
- Other
Overview
EB-003 has demonstrated ability to bind to the 5-HT2A receptor and induce neuroplasticity without eliciting significant head twitch response in mice (a predictor of hallucinogenic effects in humans). The company is completing studies required for an IND application[6][8][9].
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculesneuroplastogenic compounds
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $6.3M
- Total revenue
- $0
- Enterprise value
- $-2M
Beyond the preview
Go deeper on Enveric Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enveric Biosciences.